ArticleClinicoEconomics and outcomes research : CEOR2019

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer.

Alberto Bretoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.